Antiproteinuric effect of olmesartan in patients with IgA nephropathy

Journal of Nephrology

Volumn 22, Issue 2, 2009, Pages 224-231

  Tomino, Yasuhiko ^a   Kawamura, Tetsuya ^b   Kimura, Kenjiro ^c   Endoh, Masayuki ^d   Hosoya, Tatsuo ^b   Horikoshi, Satoshi ^a   Utsunomiya, Yasunori ^b   Yasuda, Takashi ^c   Toyoda, Masao ^d   Tsuge, Toshinao ^a   Kaneko, Kotaro ^e  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e National Hospital Organization Kasumigaura Medical Center   (Japan)

Author keywords

Blood pressure; IgA nephropathy; Normotensive; Olmesartan; Urinary protein

Indexed keywords

OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLD SWEAT; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; IMMUNOGLOBULIN A NEPHROPATHY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PATIENT COMPLIANCE; POSITIONAL VERTIGO; PROTEIN URINE LEVEL; PROTEINURIA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VISUAL DISORDER; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS; URINE;

ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, IGA; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROTEINURIA; TETRAZOLES; TREATMENT OUTCOME; URINALYSIS; YOUNG ADULT;

EID: 67649400900     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Berger J. IgA glomerular deposits in renal disease. Transplant Proc. 1969;1:939-944.
2. Hood SA, Velosa JA, Holley KE, Donadio JV Jr. IgA-IgG nephropathy: predictive indices of progressive disease. Clin Nephrol. 1981;16:55-62
3. DíAmico G, Ferrarino F, Colasanti G, Ragni A, Bestetti Bosisio M. IgA-mesangial nephropathy (Berger's disease) with rapid decline in renal function. Clin Nephrol. 1981;16:251-257.
4. Kobayashi Y, Tateno S, Hiki Y, Shigematsu H. IgA nephropathy: prognostic significance of proteinuria and histological alterations. Nephron. 1983;34:146-153.
5. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578-1583.
6. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851-856.
7. Pozzi C, Del Vecchio L, Casartelli D, et al; Adulto e Bambino Study Group. Immunopatologia Renale Study Group of the Italian Society of Nephrology. ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study. J Nephrol. 2006;19:508-514.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
9. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
10. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359-364.
11. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601-1608.
12. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448-1456.
13. Nonaka Takahashi S, Fujita T, Takahashi T, et al. TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. J Nephrol. 2008;21:53-63.
14. Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int. 2003;64:1947-1955.
15. Brenner BM, Cooper ME, Zeeuw D, et al; RENAAL Study Investigators: effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
16. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320.